News Archive

CIOMS - Real-world data and real-world evidence in regulatory decision making

12th June 2023

You are invited to comment on the below report.

Read More+

MHRA - Windsor Framework medicines announcement

11th June 2023

The Windsor Framework sets out a long-term solution for the supply of medicines into Northern Ireland. These measures will commence on 1 January 2025.

Read More+

EMA - Progress with EU-US mutual recognition agreement for inspections for veterinary medicines

7th June 2023

On 31 May 2023, the European Union and the United States have made important progress towards enabling mutual recognition of inspections of manufacturing facilities of certain veterinary products.

Read More+

EMA - Veterinary Medicines Highlights Newsletter

7th June 2023

News, activities and interviews from the Veterinary Medicines Division. Published quarterly by the European Medicines Agency.

Read More+

EMA - CTIS Newsflash -26 May 23

31st May 2023

This regular CTIS newsflash provides key updates on CTIS and links to useful reference materials.

Read More+

MHRA - New regulatory pathway set to support safe patient access to innovative medical technologies

31st May 2023

Set for launch later in 2023, the Innovative Devices Access Pathway (IDAP) will be run by the MHRA, NICE, and other partners, including the devolved administrations.

Read More+

MHRA - new recognition routes

31st May 2023

MHRA announces new recognition routes to facilitate safe access to new medicines with seven international partners

Read More+

MHRA - changes to the ICH E6 GCP Guideline

29th May 2023

Andrew Fisher, Lead Senior GCP Inspector, writes a blog about the recent changes.

Read More+

EMA - Meeting highlights from the Committee for Veterinary Medicinal Products (CVMP) 15-16 May 2023

25th May 2023

CVMP opinions on veterinary medicinal products

Read More+

FDA - Adjusting for Covariates in Randomized Clinical Trials for Drugs and Biological Products Guidance for Industry

25th May 2023

This guidance describes FDA’s current recommendations regarding adjusting for covariates in the statistical analysis of randomized clinical trials in drug2 development programs. This guidance provides recommendations for the use of covariates in the analysis of randomized, parallel group clinical trials that are applicable to both superiority trials and noninferiority trials.

Read More+